Open Access

Purification and biochemical characterization of a secreted group IIA chicken intestinal phospholipase A2

  • Aida Karray1,
  • Fakher Frikha1,
  • Yassine Ben Ali1,
  • Youssef Gargouri1 and
  • Sofiane Bezzine1Email author
Lipids in Health and Disease201110:27

https://doi.org/10.1186/1476-511X-10-27

Received: 11 December 2010

Accepted: 1 February 2011

Published: 1 February 2011

Abstract

Background

Secretory phospholipase A2 group IIA (IIA PLA2) is a protein shown to be highly expressed in the intestine of mammals. However, no study was reported in birds.

Results

Chicken intestinal group IIA phospholipase A2 (ChPLA2-IIA) was obtained after an acidic treatment (pH.3.0), precipitation by ammonium sulphate, followed by sequential column chromatographies on Sephadex G-50 and mono-S ion exchanger. The enzyme was found to be a monomeric protein with a molecular mass of around 14 kDa. The purified enzyme showed a substrate preference for phosphatidylethanolamine and phosphatidylglycerol, and didn't hydrolyse phosphatidylcholine. Under optimal assay conditions, in the presence of 10 mM NaTDC and 10 mM CaCl2, a specific activity of 160 U.mg-1 for purified ChPLA2-IIA was measured using egg yolk as substrate. The fifteen NH2-terminal amino acid residues of ChPLA2-IIA were sequenced and showed a close homology with known intestinal secreted phospholipases A2. The gene encoding the mature ChPLA2-IIA was cloned and sequenced. To further investigate structure-activity relationship, a 3D model of ChPLA2-IIA was built using the human intestinal phospholipase A2 structure as template.

Conclusion

ChPLA2-IIA was purified to homogeneity using only two chromatographic colomns. Sequence analysis of the cloned cDNA indicates that the enzyme is highly basic with a pI of 9.0 and has a high degree of homology with mammalian intestinal PLA2-IIA.

Background

Phospholipases A2 (PLA2s) hydrolyse the sn-2 bond of phospholipids resulting in the release of a fatty acid and lysophospholipid. Mammalian PLA2s are classified in three broad categories of secreted PLA2 (sPLA2) and cytosolic PLA2s which are either calcium dependent as to their catalytic activity, or calcium independent cytosolic PLA2s [1]. Secreted PLA2s are small molecular size proteins (14-19 kDa) with a rigid tertiary structure, having five to eight disulfide bonds that probably confer resistance to proteolysis and thermal denaturation [1, 2] with a highly conserved catalytic site and a Ca2+-binding loop. These secreted PLA2s were first detected in snake venom pancreatic juice and in tissues [3]. Secreted PLA2s are also expressed in a number of cell types and present in various body fluids. They participate in the first line in antimicrobial defence of the body against bacteria and other pathogens. The extensive literature on sPLA2s in inflammatory diseases has been reviewed [411].

The gene of pancreatic PLA2-IB was first isolated in 1986 [12] followed in 1989 by the cloning of non-pancreatic PLA2-IIA from rheumatoid arthritic synovial fluid [13] and blood platelets [14]. Together with pancreatic PLA2-IB, the sPLA2-IIA are the best known and biochemically characterized enzymes. Novel sPLA2 were identified in the 90th by screening nucleic acid data bases. Up to now, eleven sPLA2s have been cloned: IB, IIA, IIC, IID, IIE, IIF, III, V, X, and XIIA PLA2s together with the XIIB PLA2-like protein devoid of catalytic activity [1, 15, 16]. They express different catalytic and binding properties to natural phospholipids [17, 18].

Earlier studies have localized sPLA2-IIA in the intestine [19, 20] and in the synovial fluid of patients with rheumatoid arthritis as well as sPLA2 released from platelets [14, 21]. The concentration levels of PLA2-IIA increase in sera of patients suffering from severe acute inflammatory diseases, such as sepsis and bacterial infections [22, 23] and acute pancreatitis [24]. The sPLA2-IIA was originally localized in Paneth cells of the rat intestine [25, 26] and later on in macrophages [27, 28]. The two above mentioned cell types are both involved in the antibacterial response.

Later on it was demonstrated that the PLA2-IIA from human and mouse, with high activity on phosphatidylglycerol and bearing cationic properties (pI > 9.0), are highly bactericidal against gram positive bacteria [2933] by perturbing the anionic bacterial cell wall [34]. The bacteria digested by the intestinal PLA2 do not necessarily have to be within the intestinal lumen. Some bacteria specifically invade the intestinal mucosa from the lamina propria, as it has been postulated to occur in Whipple's disease [35]. The human PLA2-IIA enzyme shows low affinity for zwitterionic interfaces, and in the absence of interfacial binding mammalian membrane hydrolysis is not possible [36].

With the growing interest in chicken diseases, such as avian influenza, we recently focused on bird sPLA2 to further gain some functional and pathological insights. Ben Bacha et al. [37] have biochemically characterized an active thermo stable PLA2-IB from ostrich pancreas (OPLA2). Another PLA2-IB was also purified from chicken pancreas and biochemically characterized [38]. It was therefore of interest to further study some biochemical and structural properties of avian non-pancreatic PLA2 to gain more insights into their mode of action on phospholipids and to compare their properties with those of mammalian PLA2. We report here, the purification and some biochemical properties of a secreted PLA2 from chicken intestine (ChPLA2-IIA). This work reports also the cloning of the corresponding bird PLA2 cDNA and the comparison of its deduced amino acid sequence with other known mammalian PLA2. A molecular 3D model of ChPLA2-IIA is also proposed to explain some biochemical differences of ChPLA2-IIA with other intestinal and pancreatic PLA2.

Results and discussion

Determination of phospholipase activity

The PLA2 activity was measured titrimetrically at pH 9.0 and at 40°C with a pH-stat, under the standard assay conditions as described previously [39], using egg yolk (0.5% W/V) as substrate, in 30 ml of 150 mM NaCl, 10 mM NaTDC and 10 mM CaCl2. The analysis of the purified egg yolk phospholipids by thin layer chromatography revealed the presence of two spots. The major one (90%) corresponds to the phosphatidylcholine (PC, or lecithin) and the second one (10%) phosphatidylethanolamine (PE). These two phospholipids were separated by adsorption chromatography on a silica gel column. Elution was performed using stepwise ratios of chloroform/methanol. We incubated the purified PC or PE samples with ChPLA2-IB or ChPLA2-IIA respectively and a thin layer chromatography was performed as shown in Figure 1. As expected, ChPLA2-IB hydrolyzes efficiently PC and PE since the spots of these two phospholipids totally disappeared and a spot of free fatty acid appeared. In contrast, ChPLA2-IIA didn't hydrolyze PC even after a long incubation period. Interestingly, PE was totally hydrolyzed by ChPLA2-IIA similarly to what observed with ChPLA2-IB. These analytical results clearly indicate that the hydrolytic activity of ChPLA2-IIA, measured with pH-stat using egg yolk as substrate, is mainly due to the hydrolysis of the PE fraction.
Figure 1

Thin layer chromatography of PC and PE before or after incubation with ChPLA 2 -IIA or ChPLA 2 -IB. After solvent migration the silica plate was exposed to iodine vapor to reveal the various spots. Lane (1), PC. Lane (2), PC incubated with PLA2 from chicken pancreas (PLA2-IB) and showing a complete hydrolysis of the PC. Lane (3), PC incubated with PLA2 from chicken intestine (PLA2-IIA). Lane (4), PE. Lane (5), PE incubated with PLA2-IB and showing a complete hydrolysis of the PE. Lane (6), PE incubated with PLA2-IIA and showing a complete hydrolysis of the PE. Lane (7), free fatty acid C 18:1.

Purification of ChPLA2-IIA

ChPLA2-IIA was purified from the intestine mucosa using an acidic treatment, ammonium sulfate precipitation, followed by two chromatography steps on Sephadex G-50, and Mono-S Sepharose according to the procedure described in Material and Methods (Figure 2). The main steps of the purification procedures and flow sheet are summarized in Table 1. The specific activity of pure ChPLA2-IIA reaches 160 U.mg-1 when egg yolk was used as substrate, at pH 9.0 and at 40°C, in the presence of 10 mM NaTDC, and 10 mM CaCl2. The ChPLA2-IIA purification yield was about 10%. SDS-PAGE analysis of the purified ChPLA2 IIA eluted from the Mono-S column show that the enzyme exhibited one homogenous band corresponding to an apparent molecular mass of about 14 kDa (Figure 2). The calculated molecular mass, using the amino acid sequence is 13616Da. Furthermore, the calculated isoelectric pH was equal to pH 9.01.
Figure 2

Purification of ChPLA2-IIA. (A) Gel filtration chromatography of intestinal ChPLA2-IIA on Sephadex G-50. The column (1.5 cm × 34 cm) equilibrated in 20 mM Tris-HCl buffer pH 8.0 containing 20 mM CaCl2 and 2 mM benzamidine. Elution was performed with the same buffer at a flow rate of 40 ml.h-1 and 3 ml samples were collected. ChPLA2-IIA activity was measured as described in Material and methods section using egg yolk emulsion as substrate. The pooled fractions containing the PLA2 activity were indicated by horizontal line. (B) Mono-S Sepharose chromatography. The column (5 cm × 2 cm) was equilibrated with 20 mM Tris HCl buffer pH 8.0 containing 20 mM CaCl2 and 2 mM benzamidine; and then washed with the same buffer containing 0.3 M NaCl. Linear salt gradient (0.3 to 1 M NaCl, dotted line) was applied to the column; gradient chamber 75 ml; 2 ml fraction; flow rate, 40 ml/h. The pooled fractions containing the PLA2 activity were indicated by horizontal line. SDS-PAGE (15%) analysis of pure ChPLA2-IIA was inserted in Figure 2B. Lane 1, molecular mass markers (MM); Lane 2, 15 μg of proteins obtained after Sephadex G-50 chromatography; Lane 3, 15 μg of purified ChPLA2-IIA, obtained after Mono-S chromatography.

Table 1

Flow sheet of chicken intestinal phospholipase A2 purification

Purification Step

Total Activity (U)a

Total Protein (mg)b

Yield (%)

Specific activity (U/mg)

Purification Factor

Extraction

(pH 8.5)

250

5520

100

0.045

1

Acidic treatment (pH3)

123

205.5

49

0.6

13.33

(NH 4 ) 2 SO 4

Precipitation

(60%)

108

108

43

1

22.22

Sephadex G-50

95

6.41

38

14.8

328.88

MonoS Sepharose

25

0.156

10

160

3555

a) 1 Unit: μmole of fatty acid released per min using egg yolk as substrate in the presence of 10 mM NaTDC and in the presence of 10 mM CaCl2.

b) Proteins were estimated by Bradford method [30]. The experiments were conducted in triplicate.

Enzymatic properties of the purified ChPLA2-IIA

Ca2+ dependence

It is well established that Ca2+ is essential for both, catalysis and enzyme binding to the substrate [4042]. In order to investigate the effect of Ca2+ on ChPLA2-IIA activity, we studied the variation of hydrolysis rates of egg yolk phospholipids by pure ChPLA2-IIA in the presence of various Ca2+ concentrations (Figure 3A). Our results showed that no PLA2 activity can be detected in the absence of Ca2+ and in the presence of 10 mM EDTA or EGTA. In the absence of calcium chelators, the specific activity of purified ChPLA2 increases to reach 160 U.mg-1 at 10 mM CaCl2 (Figure 3A).
Figure 3

Effect of Ca 2+ and NaTDC on ChPLA2-IB and ChPLA2-IIA activities. (A) Effect of Ca2+ concentration on ChPLA2-IIA (black circle) and ChPLA2-IB (white circle) activities. Enzyme activity was measured at various concentrations of Ca2+ using egg yolk emulsion as substrate at pH 9.0 and at 40°C in the presence of 10 mM NaTDC. The star indicates the phospholipase activity measured in the absence of CaCl2 and in the presence of 10 mM EDTA or EGTA. (B) Effect of increasing concentration of bile salts (NaTDC) on ChPLA2-IIA (black circle) and ChPLA2-IB (white circle) activities. PLA2 activity was measured using egg yolk emulsion as substrate at pH 9.0 and at 40°C in the presence of 10 mM Ca2+.

These observations corroborate previous findings with porcine [20], rat [19], and human [14] intestinal PLA2. We previously reported that pancreatic chicken PLA2-IB requires only 4 mM of CaCl2 to reach its maximal activity (Figure 3A and [38]).

Bile salts dependence

Several studies have provided evidence that bile salts are tensioactive agents ensuring in their micellar form, the dispersion of the lipolytic products (of hydrolysis,) [43, 44]. Along the same line, De Haas et al. reported that micellar forms of the substrate were hydrolysed at a much higher rate than substrates molecularly dispersed by PLA2[45]. In this study, we measured the ChPLA2-IIA activity at pH 9.0 and at 40°C using egg yolk as substrate in the presence of increasing concentrations of bile salts. As shown in Figure 3B, NaTDC was required for ChPLA2-IIA activity. ChPLA2-IIA was poorly active at concentrations lower than 2 mM of NaTDC. This activity increases with increasing bile salts concentration and the maximal PLA2 activity was measured in the presence of 10 mM NaTDC. In contrast, we have presently shown, confirming our previous work, that pancreatic chicken PLA2-IB was found to be active in the absence of NaTDC and its optimal activity was found to be nearly independent of NATDC (Figure 3B and [38]. One has to recall that in the assay using egg yolk emulsion as substrate, the pancreatic PLA2 hydrolyses both PC and PE whereas the intestinal enzyme hydrolyses only PE.

Effect of temperature on ChPLA2-IIA activity and stability

Figure 4A shows that the maximal activity of ChPLA2-IIA was measured at 40°C using egg yolk as substrate in the presence of 10 mM Ca2+ and 10 mM NaTDC. Unlike pancreatic ChPLA2-IB [38] which is totally inactivated at high temperature, the ChPLA2-IIA maintained about 60% of its activity after 15 min of incubation at 60°C (Figure 4B). Comparable results were obtained with mammalian intestinal PLA2 from various species which show a good stability at high temperature [46, 47].
Figure 4

Effect of temperature and pH on ChPLA2-IB and ChPLA2-IIA. Effects of temperature (A, B) and pH (C, D) on ChPLA2-IIA (black circle) and ChPLA2-IB (white circle) activities (A, C) and stability (B, D). PLA2 were tested for activity at various temperatures (A) and pH (C) as described in material and methods. To study the stability of PLA2, 1 mg.ml-1 of each enzyme was incubated during 30 min at various temperatures (B) and pH (D). Residual PLA2 activity was measured using egg yolk as substrate in the presence of 10 mM Ca2+ and 10 mM NaTDC. For temperature stability studies, enzymes were incubated in 10 mM Tris (pH 8.0) and 10 mM CaCl2. For pH stability studies, Tris buffer was replaced by the appropriate buffer for the pH range.

Effects of pH on ChPLA2-IIA activity and stability

As shown in Figure 4C, the maximal activity of ChPLA2-IIA was measured at pH 9.0 and at 40°C using egg yolk as substrate in the presence of 10 mM Ca2+ and 10 mM NaTDC. Similar results were obtained with ChPLA2-IB and human intestinal PLA2-IIA. However, the purified ChPLA2-IIA was found to be stable between pH 3.0 and 10.0 (Figure 4D). In contrast to the ChPLA2-IB, which was found to lose its activity when incubated at pH lower than 5 [38], pure ChPLA2-IIA maintained about 50% of its activity after 15 min of incubation at pH 3.0 (see Figure 4D). It was also reported that porcine [20] rat [19] and human [14] intestinal PLA2 are stable at low pH values as compared to ChPLA2-IIA. Whereas, some pancreatic PLA2-IB are very acid and thermo stable [37, 48]

N-terminal sequence of ChPLA2-IIA

The NH2 terminal sequencing of the ChPLA2-IIA allowed unambiguously the identification of the first fourteen residues of pure enzyme. Table 2 shows that the N-terminal sequence of ChPLA2-IIA has identity at 80% with mouse, 53% with human, and 53% with porcine PLA2-IIA respectively. Pure ChPLA2-IIA exhibits a high degree of homology with mouse intestinal PLA2-IIA.
Table 2

Alignment of the N-terminal amino-acid sequence of ChPLA2-IIA with mouse, human and porcine intestinal phospholipases. Identical aminoacids are in bold, and homologous aminoacids are in italic

Chicken:

N I A Q F G I M I K E K T G K

(present work)

Mouse:

N I A Q F G E M I R L K T G K

[19]

Human:

N L V N F H R M I K L T T G K

[14]

Porcine:

D L L N F R K M I K L K T G K

[20]

Cloning and sequencing of the gene coding ChPLA2-IIA

The cDNA encoding ChPLA2-IIA was selectively amplified by RT-PCR from total mRNA extracted from chicken intestine as described in material and methods. The corresponding DNA was ligated into pET 21a(+) vector and used for transformation into E. coli DH10B cells. Several clones are selected and some of them contained a recombinant plasmid with a 500 pb EcoRI/XhoI insert. The cDNA sequencing, confirmed that the PCR product corresponds to the gene encoding for the mature ChPLA2-IIA (Figure 5). The deduced polypeptide sequence of ChPLA2-IIA, corresponding to the mature protein, comprises 123 amino acids. ChPLA2-IIA shares 45% of identity with human PLA2-IIA and 51% of identity with mouse PLA2-IIA. Residues of the catalytic diad are conserved in ChPLA2-IIA. The 14 cystein residues involved in disulfide bridges in all known PLA2 IIA are also conserved in ChPLA2-IIA suggesting also the presence of 7 disulfide bridges in its 3D structure.
Figure 5

Nucleotide sequence of the cDNA of ChPLA 2 -IIA and the deduced amino acid sequence. Sequencing was performed in triplicate with three independent PCRs. The amino acid sequence obtained by N-terminal amino-acid sequence of the pure ChPLA2-IIA is shown in italic. M1-C18 in bold, signal peptide; Y41-G49 in square, Ca2+ loop; and H64-D65 with stars, active site.

Homology modelling

To provide an insight into the biochemical properties, the structure model of the ChPLA2-IIA was built, using the 3D structure of the hPLA2 (PDB code: 1N28) as template. These two proteins shares 45% amino acid identity. The model of the ChPLA2-IIA was then subjected to molecular mechanics optimization using CHARMM27 force-field. Energy minimization (geometry optimization) was performed until the gradient of 0.01 kcal/(Å.mol) was reached. The RMS deviations involving α-carbons between the initial and the optimized models was 0.95 Å. The Ramachandran plot statistics of the final ChPLA2-IIA model and of the hPLA2, determined using the PROCHECK program, showed that 97.2%, and 100% of the residues were either in the most favored or in the additional allowed regions, respectively.

Overall 3D structure model of ChPLA2

As shown in Figure 6, the ChPLA2-IIA has a globular shape with an α/β hydrolase fold stabilized by seven disulfide bridges similar to those present in all group IIA sPLA2. The core structure consists of four α-helices (αA: Ile2-Thr13; αB: Ala17-Gly22, αC: Ala38-Ser55 and αD: Ser81-Thr103) and two short anti-parallel β-strands (β1 : Phe67-Lys70 and β2 : Gln73-Cys76) located between helix αC and αD. The catalytic Ca2+ ion is coordinated via oxygen atoms of His26 and Gly28 which belong to the Ca2+-binding loop and the two oxygen atoms, Oδ1 and Oδ2 of Asp47. The ChPLA2-IIA model showed that (O) Gly22, (O) Gly24, (O) Tyr111 and (Oδ1) Asn113 are located at an interaction distance of 2.2 Å with a second Ca2+ ion. However these residues correspond in ChPLA2-IB to Asp24, Gly26, Leu118 and Lys120, respectively. No fourth amino acid was found in a favorable position to interact with this ion in ChPLA2-IB due to the substitution of Asn113 (Oδ1) (in ChPLA2-IIA) by Lys120 (in ChPLA2-IB). This second Ca2+ ion may help the stabilization of the C-terminal (Tyr111 and Asn113) with the helix αB (Gly22, and Gly24) and furthermore the Ca2+-binding loop.
Figure 6

3D modelling structure of ChPLA2-IIA. (A) Cartoon representation the 3D model of the mature ChPLA2-IIA. Secondary structure elements labels are indicated. α-helices and β-strands are colored in red and yellow, respectively. The catalytic network and the Ca2+-binding residues are indicated and shown as sticks. The disulfide-bridges are shown in yellow. (B) Cartoon representation of the ChPLA2-IIA structure showing amino acids (represented by sticks) interacting with the substrate (PG). The substrate is indicated as a stick representation. The Ca2+ ions are represented by a blue spheres. This figure was generated using the PYMOL software.

Although ChPLA2-IIA and ChPLA2-IB share seven disulfide bridges, only six of them are structurally conserved. In ChPLA2-IB, the disulfide bridge between Cys11 and Cys77 may stabilize the N-terminal α-helix αA with one of the two short strands of an anti-parallel β-sheet (β-wing) (β2). However, in ChPLA2-IIA, one new disulfide bridge is formed between Cys48 (belong to helix αC) and C-terminal Cys123.

To get more insight on the stabilization effect of the second calcium ion, molecular dynamics simulations were carried out (1 ns) at 330°K for the minimized models of the ChPLA2-IIA in the presence and the absence of this ion. The RMSD value for the backbone atoms was used to understand the response behavior. The 2D-RMSD plot, where the root mean square deviation of every conformation to all others of a simulation is shown, demonstrated that the conformational space sampled by ChPLA2-IIA in the simulations was larger in the absence of Ca2+ ion (Figure 6).

Docking

The total accessible surface area of the ChPLA2-IIA and ChPLA2-IB were 6591 and 6522 Å2, respectively. The positive charged surface of the ChPLA2-IIA (876 Å2, 12.6%) was higher than that of ChPLA2-IB (440 Å2, 6.7%). Furthermore, the negative charged surfaces of the ChPLA2-IIA and ChPLA2-IB were 69 Å2, (1%) and 399 Å2, (6.1%), respectively.

Analysis of PLA2 structures bound to a substrate can help in understanding the interaction mode of the substrate once located in the catalytic pocket.

The docking of the substrate (PC, PE or PG) to the ChPLA2-IIA and the ChPLA2-IB protein was performed using the Molegro Virtual Docker v.4.0.2 software, respectively (data not shown). According to the protein-substrate complexes, 13 or 12 residues are in van der vaals contact with the substrate in the case the ChPLA2-IIA and ChPLA2-IB, respectively. In the case of the ChPLA2-IIA, the total interaction energy between the protein and the target substrate is -134.8, -128.4 and -137,9 kJ/mol for PC, PE or PG respectively. In the case of the ChPLA2-IB, the total interaction energy is -183.8, -142.3 and -192.2 kJ/mol for PC, PE or PG respectively. These above mentioned interaction energy may help to explain the lack of catalytic activity of the ChPLA2-IIA on PC as substrate.

Materials and methods

Materials

Benzamidine was from Fluka (Buchs, Switzerland), bovine serum albumine (BSA), anhydrous magnesium sulfate, anhydrous sodium sulfate, potassium chloride, sodium chloride, taurodeoxycholic acid sodium salt (NaTDC) and PC were purchased from Sigma Chemical (St. Louis, MO, USA); acrylamide and bis-acrylamide electrophoresis grade were from BDH (Poole, UK), marker proteins and supports of chromatography used for phospholipase purification: Sephadex G-50, MonoS sepharose, were from Pharmacia (Uppsala, Sweden); protein sequencer Procise 492 equipped with 140 C HPLC system provided from Applied Biosystems (Roissy, France); pH-stat was from Metrohm (Herisau, Switzerland).

All enzymes and reagents used in DNA manipulations were from Promega and Invitrogen (Paris, France). Oligonuclotides were synthesized by Invitrogen. E. coli strain DH10B was used as cloning host for the gene part encoding the mature phospholipase. PCR products were purified using the Wizard PCR Preps DNA purification System (Promega).

Thin-layer Silica Gel 60 plates (10 × 20 cm from Merck) were used for the separation of lipids. Lipid standards (α-L-oleic acid C 18:1) and silica gel 60 powders (70-230) were from Sigma-Aldrich (Steinheim, Germany). All solvents with HPLC grade were purchased from SDS (Peypin, France).

Lipid extraction, separation and analysis

Ten micrograms of purified ChPLA2-IB and purified ChPLA2-IIA were incubated respectively with 25 μM of pure phosphatidylcholine (PC) and phosphatidylethanol (PE) dispersion in 1 ml buffer (10 mM Tris HCl, 10 mM NaTDC and 10 mM CaCl2) at 37°C for 10 minutes. Lipolysis was stopped by adding 200 μl of 1 M HCL and mixing vigorously with 5 ml of chloroform/methanol mixture (2:1, v/v) in a 15 ml glass tube with a Teflon-lined screw cap. Lipids were immediately extracted as follows: after separation phases, the lower organic phase was transferred to a 15-ml test tube and dried over anhydrous magnesium sulphate. Once MgSO4 had precipitated, the clear organic phase was removed by centrifugation and stored at -20°C before TLC analysis.

To separate lipid classes, 1 to 50 μl of lipid extracts or lipid standards at known concentrations were first spotted onto a thin-layer silica plate. The elution of the lipids was then performed in one step with a chloroform/methanol/water (65/25/4, v/v/v) solvent mixture. Following chromatography, the plates were dried at room temperature for 10 min then immediately placed in the iodine.

Enzyme samples

The intestine from chicken was collected from a local slaughterhouse (Sfax, Tunisia). Immediately after slaughter, the most distal intestine was opened on a glass plate on ice. The content of each ileal segment was flushed twice with 100 ml of 0.15 M NaCl. Adherent mesentery was removed as completely as possible.

Purification of ChPLA2-IIA

Fifty grams of chicken intestine mucosa were suspended in 50 ml of buffer A (0.01 M Tris-HCl pH 8, 0.15 M NaCl, 0.02 M CaCl2 and 4 mM Benzamidine), and ground mechanically twice for 30 s at room temperature using the Waring Blendor system. Then, the mixture was stirred in a cold room for 1 h and centrifuged during 30 min at 12.000 rpm. The total PLA2 intestine activity obtained was 250 U.

Acidic treatment

To inactivate proteins from the pancreatic juice and secreted into the intestine, the supernatant was brought to pH 3.0 by adding 6 N HCl under gentle stirring at 0°C. Insoluble denatured proteins were removed by centrifugation during 30 min at 12.000 g and the clear supernatant was adjusted to pH 8.0 with 4 N NaOH. The recovery of PLA2 activity was of about 50%.

Ammonium sulphate precipitation

The supernatant (55 ml, 123 U) was brought to 60% saturation with solid ammonium sulphate under stirring conditions and maintained during 45 min at 4°C. After centrifugation for 30 min at 12.000 g and at 4°C, the precipitated PLA2 was resuspended in 2 ml of buffer A containing 2 mM benzamidine. Insoluble material was removed by centrifugation for 10 min at 24.000 g. The recovery of PLA2 activity was about 45%.

Filtration on Sephadex G-50

The sample containing PLA2 activity (4 ml, 108 U) was loaded on a column of sephadex G-50 (34 cm × 1.5 cm) equilibrated with buffer B (20 mM Tris-HCl, pH 8 and 20 mM CaCl2). Elution of proteins was performed with the same buffer at 40 ml.h-1. The fractions containing the PLA2 activity eluted between 1.5 and 1.8 void volumes were pooled (Figure 2A).

Cation exchange chromatography

The pooled fractions of Sephadex G-50 column containing PLA2 activity were poured into a Mono-S column (5 cm × 2 cm) equilibrated with buffer B. Under these conditions, the enzyme is adsorbed to the anionic support and the column was washed with 60 ml of the same buffer containing 0.3 M NaCl. ChPLA2-IIA was eluted by a linear salt gradient (0.3-1 M) NaCl as shown in Figure 2B.

Analytical methods

Protein concentration was determined as described by Bradford et al. [49] using BSA ( E 1 cm 1 % = 6.7 ) as reference.

Analytical polyacrylamide gel electrophoresis of proteins in the presence of sodium dodecyl sulfate (SDS-PAGE) was performed by the method of Laemmli [50]. The proteins were stained with Coomassie brilliant blue.

Amino acid sequencing

The N-terminal sequence was determined by automated Edman's degradation, using an Applied Biosystems Protein Sequencer Procise 492 equipped with 140C HPLC system.

Bacterial starins, plasmids and media

E. coli strain DH10B was used as cloning host for the gene part encoding for the mature PLA2. E. coli strain was grown in Luria-Bertani medium, supplemented with 100 μg.ml-1 ampicilline whenever plasmid maintenance was required. The plasmid pET21a(+) (Novagen) was used as cloning vector.

cDNA synthesis and amplification

Total mRNAs were isolated from chicken intestine using the single step guanidine isothiocyanate/phenol/chloroform isolation method as described by Chomczynski and Sacchi [51]. ChPLA2-IIA cDNA was obtained from total mRNAs by the reverse transcription procedure (Promega). First strand cDNAs were prepared using 10 μg of total mRNAs as template (heat-denaturated for 5 min at 70°C,) 200 U MMLV reverse transcriptase (Invitrogen), 20 pmol of each deoxynucleoside triphosphate, and 20 pmol of each primer: forward primer, 5'- GAA TTC ATG AAG CTC C TG GTG CTC CT C -3' and reverse primer, 5'- CT C GAG CTA GCA AGA GGG ACG TGA GCC -3'. The N-terminal primer was predicted, from the N-terminal sequence of the ChPLA2; however the C-terminal primer was deduced from the genome of Gallus gallus (GenBank accession number: XP 424364). Reverse transcription was carried out in a total reaction volume of 20 μl for 5 min at room temperature and 60 min at 42°C. The cDNA/RNA heteroduplex was then denaturated at 70°C for 15 min and cooled on ice.

Cloning of the mature PLA2 gene

Amplification of the specific ChPLA2-IIA cDNA was carried out by PCR using the single strand cDNAs as template with the forward and reverse primers previously described. PCR was performed in a 0.2 ml Eppendorf tube with a Gene Amp® PCR System 2700. The PCR mixture contained 20 pmol of both primers, 20 pmol of each deoxynucleoside triphosphate, 5 U pfx polymerase and polymerisation buffer in final volume of 100 μl. The single strand cDNAs were directly used as template. The thermal profile involved 35 cycles of denaturation at 94°C for 1 min, primer annealing at 60°C for 1 min, and extension at 72°C for 3 min. The PCR product (500 pb) was isolated and ligated into the EcoRI and XhoI linearised and dephosphorylated pET21a(+) vector, according to the manufacturer's protocol (Promega). Protoplasts of E. coli DH10B were transformed with the ligation mixture. The resulting recombinant plasmid was named pChPLA2. The presence of the appropriated insert was verified by restriction analysis. DNA sequences were elucidated by the dideoxynucleotide chain termination method according to a cycle sequencing protocol using thermosequenase (Amersham Pharmacia Biotech). The sequencing reactions were analysed with the DNA sequencer ABI PRISM 3100/3100-Avant Genetic Analyser (California, USA). It was performed three times, using the recombinant vector pChPLA2 as template with T7 promoter primer and the T7 reverse primer (Invitrogen).

Software for infrastructure

The sequence alignment was performed with BioEdit Version 4.8.4 software. The Molecular Operating Environment 2008.10 (MOE) software was used for homology modelling, molecular dynamics and structures visualization. Models were stereochemically evaluated by the program PROCHECK. The Visualization was performed with PyMol version 0.99beta06. Figures were generated by PyMol program.

Homology Modelling

The 3-D coordinates of the human group IIA secreted PLA2 (hPLA2) (PDB code: 1N28) was extracted from the Protein Data Bank http://www.rcsb.org. The hPLA2 structure was used as template to build a model of the ChPLA2-IIA by using the structure-modelling program Molecular Operating Environment 2008.10. The model was then subjected to molecular mechanics optimization using CHARMM27 force field, until a gradient of 0.01 kcal/(Å.mol) was reached.

Docking

The 1,2-dioctylcarbamoylglycero-3-O-phosphatidylcholine (PC), 1,2-dioctylcarbamoylglycero-3-O-phosphatidylethanolamine (PE) and 1,2-dioctylcarbamoylglycero-3-O-phosphatidylglycerol (PG) were modelled by the Molecular Operating Environment 2008.10 (MOE) software using a Simplified Molecular Input Line Entry Specification (SMILES). The Molegro Virtual Docker v.4.0.2 software was used for docking substrates, PC, PE or PG to the ChPLA2-IIA and the ChPLA2-IB protein, respectively.

The potential binding sites (also referred to as cavities or active sites) was being identified using the built-in cavity detection algorithm, molecular surface with 0.5 Å grid resolutions and 1.2 Å Probe size.

After preparation of the protein and the ligand, the docking was performed using MolDock Score function, MolDock SE search algorithm, 10 runs, energy minimization and optimize H-Bonds after docking, 2500 iterations and 500 steps Simplex Evolution to generate the best five poses scores which were visually analyzed. Only one of these poses correctly bind to the active site with a high score was used. The protein-substrate complex was then subjected to molecular mechanics optimization using CHARMM27 force field as described previously. The Score of the final protein-substrate complex was evaluated using the total interaction energy between the active site and the substrate.

Statistical analysis

All the results in figures and text are the average of at least three replicate experiments. They were statistically analyzed with SPSS software (version 100), using the Duncan test performed after analysis of variance (ANOVA).

Abbreviation

PLA2

phospholipase A2

sPLA2

secreted PLA2

ChPLA2-IB: 

Group IB chicken pancreatic PLA2

ChPLA2-IIA: 

Group IIA chicken intestinal PLA2

hPLA2-IIA: 

Group IIA human PLA2

NaTDC: 

taurodeoxycholic acid sodium salt

PC: 

phosphtidylcholine

PE: 

phosphatidylethanolamine

TLC: 

thin layer chromatography

ns: 

nanosecond. MMLV: Moloney murine leukemia virus.

Declarations

Acknowledgements

This work represents a part of thesis of A. Karray. It was supported by DGRST granted to the "Laboratoire de Biochimie et de Génie Enzymatique des Lipases". The authors highly acknowledge Dr Robert Verger (EIPL-CNRS, Marseille-France) for his fruitful help and discussion during the preparation of this work. Our thanks are due to Pr H. Mejdoub (FSS, Tunisia) for the sequencing of the NH2-terminal of ChPLA2-IIA.

Authors’ Affiliations

(1)
Laboratoire de Biochimie et de Génie Enzymatique des Lipases, ENIS Route de Soukra, University of Sfax

References

  1. Six DA, Dennis EA: The expanding superfamily of phospholipase A(2) enzymes: classification and characterization. Biochim Biophys Acta. 2000, 1488 (1-2): 1-19.View ArticlePubMedGoogle Scholar
  2. Balsinde J, Balboa MA, Insel PA, Dennis EA: Regulation and inhibition of phospholipase A2. Annu Rev Pharmacol Toxicol. 1999, 39: 175-189. 10.1146/annurev.pharmtox.39.1.175View ArticlePubMedGoogle Scholar
  3. Valentin E, Lambeau G: Increasing molecular diversity of secreted phospholipases A(2) and their receptors and binding proteins. Biochim Biophys Acta. 2000, 1488 (1-2): 59-70.View ArticlePubMedGoogle Scholar
  4. Nevalainen TJ, Haapanen TJ: Distribution of pancreatic (group I) and synovial-type (group II) phospholipases A2 in human tissues. Inflammation. 1993, 17 (4): 453-464. 10.1007/BF00916585View ArticlePubMedGoogle Scholar
  5. Yoshikawa T, Naruse S, Kitagawa M, Ishiguro H, Nakae Y, Ono T, Hayakawa T: Effect of a new inhibitor of type II phospholipase A2 on experimental acute pancreatitis in rats. Pancreas. 1999, 19 (2): 193-198. 10.1097/00006676-199908000-00013View ArticlePubMedGoogle Scholar
  6. Pfeilschifter J, Schalkwijk C, Briner VA, van den Bosch H: Cytokine-stimulated secretion of group II phospholipase A2 by rat mesangial cells. Its contribution to arachidonic acid release and prostaglandin synthesis by cultured rat glomerular cells. J Clin Invest. 1993, 92 (5): 2516-2523. 10.1172/JCI116860PubMed CentralView ArticlePubMedGoogle Scholar
  7. Hurt-Camejo E, Camejo G, Peilot H, Oorni K, Kovanen P: Phospholipase A(2) in vascular disease. Circ Res. 2001, 89 (4): 298-304. 10.1161/hh1601.095598View ArticlePubMedGoogle Scholar
  8. Bidgood MJ, Jamal OS, Cunningham AM, Brooks PM, Scott KF: Type IIA secretory phospholipase A2 up-regulates cyclooxygenase-2 and amplifies cytokine-mediated prostaglandin production in human rheumatoid synoviocytes. J Immunol. 2000, 165 (5): 2790-2797.View ArticlePubMedGoogle Scholar
  9. Menschikowski M, Hagelgans A, Siegert G: Secretory phospholipase A2 of group IIA: is it an offensive or a defensive player during atherosclerosis and other inflammatory diseases?. Prostaglandins Other Lipid Mediat. 2006, 79 (1-2): 1-33. 10.1016/j.prostaglandins.2005.10.005View ArticlePubMedGoogle Scholar
  10. Rosenson RS, Gelb MH: Secretory phospholipase A2: a multifaceted family of proatherogenic enzymes. Curr Cardiol Rep. 2009, 11 (6): 445-451. 10.1007/s11886-009-0064-2View ArticlePubMedGoogle Scholar
  11. Sullivan CP, Seidl SE, Rich CB, Raymondjean M, Schreiber BM: Secretory phospholipase A2, group IIA is a novel serum amyloid A target gene: activation of smooth muscle cell expression by an interleukin-1 receptor-independent mechanism. J Biol Chem. 2010, 285 (1): 565-575. 10.1074/jbc.M109.070565PubMed CentralView ArticlePubMedGoogle Scholar
  12. Seilhamer JJ, Randall TL, Yamanaka M, Johnson LK: Pancreatic phospholipase A2: isolation of the human gene and cDNAs from porcine pancreas and human lung. DNA. 1986, 5 (6): 519-527.View ArticlePubMedGoogle Scholar
  13. Seilhamer JJ, Pruzanski W, Vadas P, Plant S, Miller JA, Kloss J, Johnson LK: Cloning and recombinant expression of phospholipase A2 present in rheumatoid arthritic synovial fluid. J Biol Chem. 1989, 5 (10): 5335-5338.Google Scholar
  14. Kramer RM, Hession C, Johansen B, Hayes G, McGray P, Chow EP, Tizard R, Pepinsky RB: Structure and properties of a human non-pancreatic phospholipase A2. J Biol Chem. 1989, 264 (10): 5768-5775.PubMedGoogle Scholar
  15. Rouault M, Bollinger JG, Lazdunski M, Gelb MH, Lambeau G: Novel mammalian group XII secreted phospholipase A2 lacking enzymatic activity. Biochemistry. 2003, 42 (39): 11494-11503. 10.1021/bi0349930View ArticlePubMedGoogle Scholar
  16. Schaloske RH, Dennis EA: The phospholipase A2 superfamily and its group numbering system. Biochim Biophys Acta. 2006, 1761 (11): 1246-1259.View ArticlePubMedGoogle Scholar
  17. Bezzine S, Koduri RS, Valentin E, Murakami M, Kudo I, Ghomashchi F, Sadilek M, Lambeau G, Gelb MH: Exogenously added human group X secreted phospholipase A(2) but not the group IB, IIA, and V enzymes efficiently release arachidonic acid from adherent mammalian cells. J Biol Chem. 2000, 275 (5): 3179-3191. 10.1074/jbc.275.5.3179View ArticlePubMedGoogle Scholar
  18. Singer AG, Ghomashchi F, Le Calvez C, Bollinger J, Bezzine S, Rouault M, Sadilek M, Nguyen E, Lazdunski M, Lambeau G: Interfacial kinetic and binding properties of the complete set of human and mouse groups I, II, V, X, and XII secreted phospholipases A2. J Biol Chem. 2002, 277 (50): 48535-48549. 10.1074/jbc.M205855200View ArticlePubMedGoogle Scholar
  19. Mansbach CM, Pieroni G, Verger R: Intestinal phospholipase, a novel enzyme. J Clin Invest. 1982, 69 (2): 368-376. 10.1172/JCI110460PubMed CentralView ArticlePubMedGoogle Scholar
  20. Verger R, Ferrato F, Mansbach CM, Pieroni G: Novel intestinal phospholipase A2: purification and some molecular characteristics. Biochemistry. 1982, 21 (26): 6883-6889. 10.1021/bi00269a040View ArticlePubMedGoogle Scholar
  21. Pruzanski W, Vadas P, Stefanski E, Urowitz MB: Phospholipase A2 activity in sera and synovial fluids in rheumatoid arthritis and osteoarthritis. Its possible role as a proinflammatory enzyme. J Rheumatol. 1985, 12 (2): 211-216.PubMedGoogle Scholar
  22. Crowl RM, Stoller TJ, Conroy RR, Stoner CR: Induction of phospholipase A2 gene expression in human hepatoma cells by mediators of the acute phase response. J Biol Chem. 1991, 266 (4): 2647-2651.PubMedGoogle Scholar
  23. Nevalainen TJ: Serum phospholipases A2 in inflammatory diseases. Clin Chem. 1993, 39 (12): 2453-2459.PubMedGoogle Scholar
  24. Nevalainen TJ, Hietaranta AJ, Gronroos JM: Phospholipase A2 in acute pancreatitis: new biochemical and pathological aspects. Hepatogastroenterology. 1999, 46 (29): 2731-2735.PubMedGoogle Scholar
  25. Senegas-Balas F, Balas D, Verger R, de Caro A, Figarella C, Ferrato F, Lechene P, Bertrand C, Ribet A: Immunohistochemical localization of intestinal phospholipase A2 in rat paneth cells. Histochemistry. 1984, 81 (6): 581-584. 10.1007/BF00489538View ArticlePubMedGoogle Scholar
  26. Qu XD, Lloyd KC, Walsh JH, Lehrer RI: Secretion of type II phospholipase A2 and cryptdin by rat small intestinal Paneth cells. Infect Immun. 1996, 64 (12): 5161-5165.PubMed CentralPubMedGoogle Scholar
  27. Murakami M, Nakatani Y, Atsumi G, Inoue K, Kudo I: Regulatory functions of phospholipase A2. Crit Rev Immunol. 1997, 17 (3-4): 225-283.View ArticlePubMedGoogle Scholar
  28. Balsinde J, Dennis EA: Distinct roles in signal transduction for each of the phospholipase A2 enzymes present in P388D1 macrophages. J Biol Chem. 1996, 271 (12): 6758-6765. 10.1074/jbc.271.12.6758View ArticlePubMedGoogle Scholar
  29. Weinrauch Y, Abad C, Liang NS, Lowry SF, Weiss J: Mobilization of potent plasma bactericidal activity during systemic bacterial challenge. Role of group IIA phospholipase A2. J Clin Invest. 1998, 102 (3): 633-638. 10.1172/JCI3121PubMed CentralView ArticlePubMedGoogle Scholar
  30. Gronroos JO, Salonen JH, Viander M, Nevalainen TJ, Laine VJ: Roles of group IIA phospholipase A2 and complement in killing of bacteria by acute phase serum. Scand J Immunol. 2005, 62 (4): 413-419. 10.1111/j.1365-3083.2005.01678.xView ArticlePubMedGoogle Scholar
  31. Harwig SS, Tan L, Qu XD, Cho Y, Eisenhauer PB, Lehrer RI: Bactericidal properties of murine intestinal phospholipase A2. J Clin Invest. 1995, 95 (2): 603-610.PubMed CentralView ArticlePubMedGoogle Scholar
  32. Nevalainen TJ, Graham GG, Scott KF: Antibacterial actions of secreted phospholipases A2. Review. Biochim Biophys Acta. 2008, 1781 (1-2): 1-9.View ArticlePubMedGoogle Scholar
  33. Koduri RS, Gronroos JO, Laine VJ, Le Calvez C, Lambeau G, Nevalainen TJ, Gelb MH: Bactericidal properties of human and murine groups I, II, V, X, and XII secreted phospholipases A(2). J Biol Chem. 2002, 277 (8): 5849-5857. 10.1074/jbc.M109699200View ArticlePubMedGoogle Scholar
  34. Birts CN, Barton CH, Wilton DC: Catalytic and non-catalytic functions of human IIA phospholipase A2. Trends Biochem Sci. 2010, 35 (1): 28-35. 10.1016/j.tibs.2009.08.003View ArticlePubMedGoogle Scholar
  35. Marth T: New insights into Whipple's disease - a rare intestinal inflammatory disorder. Digestive Diseases. 2009, 27 (4): 494-501. 10.1159/000233288View ArticlePubMedGoogle Scholar
  36. Bezzine S, Bollinger JG, Singer AG, Veatch SL, Keller SL, Gelb MH: On the binding preference of human groups IIA and X phospholipases A2 for membranes with anionic phospholipids. J Biol Chem. 2002, 277 (50): 48523-48534. 10.1074/jbc.M203137200View ArticlePubMedGoogle Scholar
  37. Ben Bacha A, Gargouri Y, Bezzine S, Mosbah H, Mejdoub H: Ostrich pancreatic phospholipase A(2): Purification and biochemical characterization. J Chromatogr B Analyt Technol Biomed Life Sci. 2007, 857 (1): 108-114. 10.1016/j.jchromb.2007.07.012View ArticlePubMedGoogle Scholar
  38. Karray A, Frikha F, Ben Bacha A, Ben Ali Y, Gargouri Y, Bezzine S: Biochemical and molecular characterization of purified chicken pancreatic phospholipase A2. Febs J. 2009, 276 (16): 4545-4554. 10.1111/j.1742-4658.2009.07160.xView ArticlePubMedGoogle Scholar
  39. de Haas GH, Postema NM, Nieuwenhuizen W, van Deenen LL: Purification and properties of an anionic zymogen of phospholipase A from porcine pancreas. Biochim Biophys Acta. 1968, 159 (1): 118-129.View ArticlePubMedGoogle Scholar
  40. Fleer EA, Puijk WC, Slotboom AJ, de Haas GH: Modification of arginine residues in porcine pancreatic phospholipase A2. Eur J Biochem. 1981, 116 (2): 277-284. 10.1111/j.1432-1033.1981.tb05330.xView ArticlePubMedGoogle Scholar
  41. Scott DL, Otwinowski Z, Gelb MH, Sigler PB: Crystal structure of bee-venom phospholipase A2 in a complex with a transition-state analogue. Science. 1990, 250 (4987): 1563-1566. 10.1126/science.2274788View ArticlePubMedGoogle Scholar
  42. Verger R, Mieras MC, de Haas GH: Action of phospholipase A at interfaces. J Biol Chem. 1973, 248 (11): 4023-4034.PubMedGoogle Scholar
  43. Evenberg A, Meyer H, Verheij HM, de Haas GH: Isolation and properties of prophospholipase A2 and phospholipase A2 from horse pancreas and horse pancreatic juice. Biochim Biophys Acta. 1977, 491 (1): 265-274.View ArticlePubMedGoogle Scholar
  44. Nieuwenhuizen W, Steenbergh P, de Haas GH: The isolation and properties of two prephospholipases A2 from porcine pancreas. Eur J Biochem. 1973, 40 (1): 1-7. 10.1111/j.1432-1033.1973.tb03161.xView ArticlePubMedGoogle Scholar
  45. de Haas GH, Bonsen PP, Pieterson WA, van Deenen LL: Studies on phospholipase A and its zymogen from porcine pancreas. 3. Action of the enzyme on short-chain lecithins. Biochim Biophys Acta. 1971, 239 (2): 252-266.View ArticlePubMedGoogle Scholar
  46. Scott DL, Sigler PB: Structure and catalytic mechanism of secretory phospholipases A2. Adv Protein Chem. 1994, 45: 53-88. full_textView ArticlePubMedGoogle Scholar
  47. Scott DL, Sigler PB: The structural and functional roles of calcium ion in secretory phospholipases A2. Adv Inorg Biochem. 1994, 10: 139-155.PubMedGoogle Scholar
  48. Bacha AB, Gargouri Y, Bezzine S, Mejdoub H: Purification and biochemical characterization of phospholipase A2 from dromedary pancreas. Biochim Biophys Acta. 2006, 1760 (8): 1202-1209.View ArticlePubMedGoogle Scholar
  49. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976, 72: 248-254. 10.1016/0003-2697(76)90527-3View ArticlePubMedGoogle Scholar
  50. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970, 227 (5259): 680-685. 10.1038/227680a0View ArticlePubMedGoogle Scholar
  51. Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987, 162 (1): 156-159. 10.1016/0003-2697(87)90021-2View ArticlePubMedGoogle Scholar

Copyright

© Karray et al; licensee BioMed Central Ltd. 2011

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.